Needham Reiterates Buy on OncoCyte, Maintains $4.25 Price Target

Benzinga · 04/08 12:18
Needham analyst Mike Matson reiterates OncoCyte (NASDAQ:OCX) with a Buy and maintains $4.25 price target.